Form 4: CareDx CFO Smith Boosts Stake with RSU, PRSU Awards

CareDx, Inc. Chief Financial Officer Nathan Smith reported significant acquisitions of restricted stock units and performance-based restricted stock units, alongside a tax-related share disposition.

Summary

• Nathan Smith, Chief Financial Officer of CareDx, Inc. (CDNA), reported transactions on February 2, 2026.
• Acquired 33,000 Restricted Stock Units (RSUs) with a vesting schedule beginning April 6, 2027, and fully vesting by April 6, 2030, contingent on continuous employment.
• Acquired 7,875 Performance Restricted Stock Units (PRSUs) which were earned upon the achievement of specific performance criteria certified by the Compensation and Human Capital Committee on February 2, 2026.
• Disposed of 3,859 shares of Common Stock at a price of $20.42 per share to satisfy tax withholding obligations related to the PRSU vesting.
• Following these transactions, Smith's direct beneficial ownership of Common Stock is 79,016 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive. The acquisition of significant equity awards, especially performance-based units, signals management's achievement of company goals and continued alignment with shareholder interests, despite a routine tax-related share disposition.

Positives

• Acquisition of 33,000 Restricted Stock Units (RSUs) indicates future equity participation and aligns management interests with shareholders.
• Earning of 7,875 Performance Restricted Stock Units (PRSUs) signifies the achievement of specific company performance criteria.

Negatives

• Disposition of 3,859 shares at $20.42 to cover tax withholding obligations reduces direct share ownership.

Risks

• The vesting of RSUs and PRSUs is subject to the Reporting Person's continuous employment, posing a risk to the full realization of these awards if employment ceases.

Future Outlook

The vesting schedule for the 33,000 RSUs extends until April 6, 2030, contingent on Nathan Smith's continuous employment, indicating a long-term incentive structure for the Chief Financial Officer.

Industry Context

StockSavvy.ai notes that insider transactions, particularly equity awards like RSUs and PRSUs, are common compensation mechanisms designed to align executive interests with long-term shareholder value. The earning of PRSUs suggests the company met specific performance targets, which can be viewed positively by the market. The subsequent sale of shares for tax withholding is a standard practice and not typically indicative of a lack of confidence.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of restricted stock units (RSUs) and performance restricted stock units (PRSUs) as executive compensation is a widely adopted practice across the biotechnology and healthcare diagnostics industry, including peers like Natera (NTRA) and Veracyte (VCYT).
• The vesting schedules, often tied to multi-year employment and performance metrics, are consistent with industry benchmarks aimed at executive retention and performance incentives.
• Similar long-term incentive plans are common at companies such as Illumina (ILMN) and Guardant Health (GH), where executives receive equity awards that vest over several years, often with performance hurdles.

Stakeholder Impact

• Shareholders: Increased alignment of CFO's interests with long-term shareholder value through equity awards. Achievement of performance criteria for PRSUs could indicate positive operational execution.
• Employees: The compensation structure for the CFO may reflect broader company compensation strategies, potentially influencing employee morale and retention.

Next Steps

• Continued vesting of the 33,000 Restricted Stock Units (RSUs) on a schedule beginning April 6, 2027, and concluding by April 6, 2030.

Key Dates

Recommendation

This Form 4 filing primarily details routine insider compensation and tax-related share dispositions. While the acquisition of RSUs and PRSUs is a positive signal of management alignment and performance achievement, it does not provide sufficient new information regarding the company's fundamental business operations, financial health, or strategic direction to warrant a change from a "hold" position. Investors should consider this in the broader context of CareDx's overall financial performance and market position.

Keywords

CareDx, CDNA, Nathan Smith, CFO, Form 4, Insider Trading, Restricted Stock Units, RSUs, Performance Restricted Stock Units, PRSUs, Stock Compensation, Equity Awards, Beneficial Ownership